top of page

Cambridge, MA based Lytica Therapeutics is trying to make antibody-drug conjugates more efficient by designing the antibody portion in a way that makes cells internalize them better

Co-Founder and CEO Rida Mourtada describes how Lytica is adding a peptidic sequence to antibodies to improve their internalization into cells, with a lead ADC program targeting folate receptor alpha.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

SAV_Logo_2024.png

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

bottom of page